Merck announces top-line results from phase 3 trials evaluating Gefapixant

Gefapixant is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough. (Credit: Bruno /Germany from Pixabay)